Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller Life Science Investing
Cizzle Brands Corporation Releases Fiscal Q3 2026 Results; Reports First Positive Adjusted EBITDA Quarter with Year-Over-Year Revenue Up 253% Biotech Investing
Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference Life Science Investing
Seer Board of Directors Issues Letter to Shareholders Highlighting the Company's Significant Scientific Progress and Addressing Radoff and Torok's Short-Sighted Campaign Life Science Investing
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 Life Science Investing
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Life Science Investing
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia Life Science Investing
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab Combination Presented at the 2026 European Hematology Association Congress Plenary Showed Prolonged Progression Free Survival Life Science Investing
Britannia Life Sciences Announces $5.3 Million Acquisition of Commercial Equipment Loan Portfolio Life Science Investing
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting Life Science Investing
